A5042837238- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Hereditary Neurological Disorders
- Polyomavirus and related diseases
- Systemic Sclerosis and Related Diseases
- Genetic Neurodegenerative Diseases
- Neurological diseases and metabolism
- Viral Infections and Immunology Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Myasthenia Gravis and Thymoma
- Alcohol Consumption and Health Effects
- Neurological Disease Mechanisms and Treatments
- Mycobacterium research and diagnosis
- Cholinesterase and Neurodegenerative Diseases
- Cytokine Signaling Pathways and Interactions
- Prion Diseases and Protein Misfolding
- Cancer therapeutics and mechanisms
- Head and Neck Surgical Oncology
- Bone Tumor Diagnosis and Treatments
- SARS-CoV-2 and COVID-19 Research
- Botulinum Toxin and Related Neurological Disorders
- Radiopharmaceutical Chemistry and Applications
- Acute Lymphoblastic Leukemia research
- Lipid metabolism and disorders
- Rheumatoid Arthritis Research and Therapies
Complexo Hospitalario Universitario A Coruña
2021
Complejo Hospitalario Universitario de Santiago
2014-2020
Universidade de Santiago de Compostela
2015-2018
<h3>Objective</h3> To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. <h3>Methods</h3> Retrospective multicenter registry patients MS suspected or confirmed diagnosis available disease course (mild = ambulatory; severe hospitalization; critical intensive care unit/death). Cases were analyzed for associations between identifying risk...
Ataxia and hereditary spastic paraplegia are rare neurodegenerative syndromes. We aimed to determine the prevalence of these disorders in Spain 2019.We conducted a cross-sectional, multicentre, retrospective, descriptive study patients with ataxia between March 2018 December gathered data from total 1933 11 autonomous communities, provided by 47 neurologists or geneticists. Mean (SD) age our sample was 53.64 (20.51) years; 938 were men (48.5%) 995 women (51.5%). The genetic defect...
To analyze the frequency and demographic characteristics of multiple sclerosis (MS) in Council Santiago de Compostela (SPAIN).The patients diagnosed with MS according to McDonald 2010 diagnostic criteria were identified within population District Compostela. Several sources used (records databases from Hospital, General Practitioners, Private Clinics, Patients Association). Demographic clinical data obtained electronic files.The incidence between 2015 was 8/100 000/year (95% CI: 6-10),...
Background: Gait disorder is very prevalent in multiple sclerosis. After 15 years of disease progression, 50% patients need assistive devices for walking. Materials & methods: We performed a multicenter observational study, including sclerosis with an Expanded Disability Status Scale score between 4.0 and 7.0, normal kidney function no previous history seizures. Results: The study sample comprised 138 average age 50.3 median 6.0. treatment, significant reduction was observed both the Timed...
Las ataxias (AT) y paraparesias espásticas hereditarias (PEH) son síndromes neurodegenerativos raros. Nos proponemos conocer la prevalencia de las AT PEH en España 2019. Estudio transversal, multicéntrico, descriptivo retrospectivo los pacientes con PEH, desde marzo 2018 a diciembre 2019 toda España. Se obtuvo información 1.933 procedentes 11 Comunidades Autónomas, 47 neurólogos o genetistas. Edad media: 53,64 años ± 20,51 desviación estándar (DE); 920 varones (50,8%), 889 mujeres (49,2%)....
Aim: To evaluate the effect of natalizumab on progression brain atrophy in multiple sclerosis (MS) patients and to search for a clinical or radiological marker atrophy. Patients methods: We retrospectively recorded demographic data, as well corpus callosum index (CCI) using MRI, MS treated with 1–4 years. Results: In study population (n = 29), baseline mean CCI was 0.37 ± 0.04 final 0.36 0.04. 17 did not develop during follow-up. There no statistically significant relationship between...
The safety and effectiveness of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) has been demonstrated clinical trials. However, due to the limitations these trials, it is important know how condition behaves under long-term practice conditions.To determine RRMS by means annual evaluation "no evidence disease activity" (NEDA) parameter, which includes number relapses, disability (measured Expanded Disability Status Scale), brain MRI parameters.We performed a...
Fampridine is the only drug approved for treatment of walking impairment in multiple sclerosis. Around a third patients on obtained an improvement speed during development phase. The effects are clinically significant, appear soon after start and long-lasting, but disappear withdrawn. In real-world setting, number with significant response to seems be higher (around 70%). tolerance good, mild moderate, transient adverse events. most commonly reported insomnia, headache, fatigue, back pain,...
Introduction. The effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS) have been proven clinical trials. Yet,due to their limitations,it is important know how it behaves under everyday practice conditions. Hence,the aim this study evaluate the after 12 months’ usage Galicia. Patients methods. We conducted a retrospective,multi-centre (n = 8) RRMS who were treated one or more doses fingolimod,0.5 mg/day. Effectiveness was assessed -annualised...
OBJECTIVE: Our main objective was analyze the evolution of cerebral atrophy in Multiple Sclerosis (MS) patients on treatment with Natalizumab. BACKGROUND: Axonal damage has been shown MS patients, even early phase, conditioning and disability. An accesible form quantify is Corpus Callosum Index (CCI), which a low interobserver variability good correlation other indices. In MS, an anual average decline CCI 0,01+0,02 demonstrated. DESIGN/METHODS: All Natalizumab during one year or more were...
OBJECTIVE: We report a female with an early onset familial spastic paraplegia (FSP) phenotype, who carries mutation of the ABCD1 gene. BACKGROUND: Adrenomyeloneuropathy (AMN), is X-linked recessive disorder, characterized by impaired peroxisomal beta-oxidation very long-chain fatty acids (VLCFA) and their accumulation in plasma all tissues. It was assumed that carriers remain asymptomatic, however many them develop mild neurological abnormalities. DESIGN/METHODS: A 43-year-old without...
April 27, 2018April 10, 2018Free AccessAlemtuzumab treatment in Multiple Sclerosis: real clinical experience the Northwest of Spain (P6.352)Ana Lopez Real, Ines Gonzalez Suarez, Eva Costa Arpin, Antonio Pato Pato, Elena Alvarez Rodriguez, Ana Rodriguez Regal, García-Pelayo Rodríguez, … Show All , Maria Dolores Garcia Bargo, Miguel Llaneza Gonzalez, Dulce Solar Sanchez, Agustin Oterino Duran, and Joaquin Peña Martinez FewerAuthors Info & AffiliationsApril 2018 issue90...
La efectividad y seguridad de natalizumab en pacientes con esclerosis múltiple remitente recurrente (EMRR) se demostró ensayos clínicos. Sin embargo, por las limitaciones estos es importante saber cómo comporta condiciones práctica clínica a largo plazo. Conocer la eficacia plazo EMRR mediante evaluación anual del no evidence of disease activity (NEDA), que incluye número brotes, discapacidad medida EDSS parámetros RM cerebral. Estudio retrospectivo multicéntrico (n = 3) tratados una o más...
April 23, 2018April 10, 2018Free AccessA new electronic and brief neuropsychological scale to detect cognitive impairment (CI) in patients with multiple sclerosis (MS): Validation study of the MS-COG-e (P2.421)José Meca Lallana, José María Prieto González, Isabel Jimenez Martín, Judith Veiga, Rafael Carles Dies, Javier Olascoaga Urtaza, Estefania García Molina, … Show All , Rocio Hernández Clares, Ester Carreon Guarnizo, Ioana Croitoru, Eva Costa Arpín, Cerdán Sánchez, Andone Sistiaga...